Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sorting nexin 13 (SNX13) is a multifunctional protein containing both PX (phosphoinositide-binding) and RGS (regulator of G protein signaling) domains, classifying it in both the sorting nexin and RGS protein families[1][2][3][5]. SNX13 acts as a molecular brake on cholesterol export from lysosomes and structures ER–lysosome contacts, contributing to the regulation of lipid homeostasis in cells[1]. It also serves as a GTPase activating protein specifically for Gαs, thus linking G protein–mediated signaling to vesicular trafficking processes[1][2]. SNX13 delays epidermal growth factor receptor degradation by regulating lysosomal trafficking, indicating a role in receptor sorting and lysosomal targeting[1][3]. Genetic deletion of SNX13 in mice leads to severe developmental abnormalities and embryonic lethality, primarily due to disrupted endosomal-lysosomal trafficking and nutrient uptake[3]. While SNX13 is critical to cellular homeostasis and development, there are currently no known drugs or clinical biomarkers that target or utilize this molecule[1][2][3].
Not applicable (no drugs directly targeting SNX13 are described)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sorting nexin 13 (SNX13).